Psychedelic clinical trials in Australia
Every psychedelic trial on ClinicalTrials.gov with a site in Australia, set beside the United States. ANZCTR-only registrations are not yet included, so the Australian figures are a lower bound.
Fetched from ClinicalTrials.gov API v2.
- Registered
- 7Australia268United States
- 0.26 and 0.79 per million residents
- Registered as recruiting
- 2Australia89United States
- 0.07 and 0.26 per million residents
- Phase 3
- 2Australia23United States
- Includes Phase 2/3
- Completed
- 3Australia99United States
- 0.11 and 0.29 per million residents
Trials with an Australian site
Open a row for dates, sponsor and site cities. The only link is to the registry record.
7 of 7 trials shown
| Details | Condition | State | |||||
|---|---|---|---|---|---|---|---|
| A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397 · Cybin IRL LimitedPsilocin analogues · Phase 3 · Registered as recruiting | Psilocin analogues | Depression | Phase 3 | Recruiting | NSW, QLD, VIC | Dec 2025 | |
| Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment DisorderNCT07072728 · Psyence Australia Pty LtdPsilocybin · Phase 2 · Registered as recruiting | Psilocybin | Serious illness distress | Phase 2 | Recruiting | VIC, WA | Oct 2025 | |
| Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)NCT06605105 · Cybin IRL LimitedPsilocin analogues · Phase 3 · Enrolling by invitation | Psilocin analogues | Depression | Phase 3 | Enrolling by invitation | QLD, VIC | Jul 2025 | |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy ParticipantsNCT06643637 · MycoMedica Life Sciences PBCPsilocybin · Phase 1 · Completed | Psilocybin | Healthy volunteers | Phase 1 | Completed | SA | Nov 2024 | |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy ParticipantsNCT06326606 · MycoMedica Life Sciences PBCPsilocybin · Phase 1 · Completed | Psilocybin | Healthy volunteers | Phase 1 | Completed | SA | Mar 2024 | |
| MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress DisorderNCT05709353 · University of SydneyMDMA · Phase 2 · Unknown status | MDMA | PTSD, Substance use | Phase 2 | Unknown status | NSW, VIC | Sep 2023 | |
| BPL-003 Efficacy and Safety in Treatment Resistant DepressionNCT05870540 · Beckley Psytech Limited5-MeO-DMT · Phase 2 · Completed | 5-MeO-DMT | Depression | Phase 2 | Completed | NSW, VIC | Sep 2023 |
Australia and the United States compared
AU Australia, 7 trials. US United States, 268 trials. Bars show each country's share of its own trials; counts sit beside them.
| Measure | Australia | per million | United States | per million |
|---|---|---|---|---|
| Registered | 7 | 0.26 | 268 | 0.79 |
| Registered as recruiting | 2 | 0.07 | 89 | 0.26 |
| Phase 2/3 or Phase 3 | 2 | 0.07 | 23 | 0.07 |
| Completed | 3 | 0.11 | 99 | 0.29 |
| Industry lead sponsor | 6 | 0.22 | 47 | 0.14 |
Population used: Australia 27.2 million (Australian Bureau of Statistics, National, state and territory population, 30 June 2024); United States 340.1 million (US Census Bureau, Vintage 2024 national population estimate, 1 July 2024). 3 trials have sites in both countries and are counted in both columns.
Phase as labelled on the registry. Behavioural and device studies are often labelled not applicable.
Overall status of the whole trial on the fetch date, not of each site.
A trial that studies two compounds is counted under both, so shares can add to more than 100%.
The filled part is trials whose lead sponsor the registry classes as industry. Everything else (universities, hospitals, government, individuals) is the unfilled part.
Year each record was first posted on the registry. The two panels use different vertical scales; the current year is incomplete.
What the comparison shows
ClinicalTrials.gov lists 7 trials with an Australian site and 268 with a United States site: 0.26 and 0.79 per million residents.
Basis: Counts of records in this snapshot divided by 2024 resident population (Australia 27.2 million, United States 340.1 million). Trials registered only on ANZCTR are not counted, which lowers the Australian figure.
4 compound and condition pairings appear in a Phase 2/3 or Phase 3 trial with a United States site but in no trial with an Australian site: LSD for anxiety, LSD for depression, Psilocybin for PTSD and Psilocybin for depression.
Basis: 23 United States trials labelled Phase 2/3 or Phase 3, compared with all 7 Australian-site trials at any phase. Condition groups are assigned by keyword rules on registry condition terms.
Australian-site trials cover Psilocybin (3), MDMA (1), Psilocin analogues (2) and 5-MeO-DMT (1). Compounds with United States trials and no Australian site on this registry: LSD (10), DMT (6), Other novel psychedelics (5), Ibogaine (2) and Ayahuasca (1).
Basis: Trials by compound; a trial that studies two compounds is counted under both. Figures in brackets are trial counts.
Industry is the lead sponsor of 86% of Australian-site trials (6 of 7) and 18% of United States trials (47 of 268).
Basis: The registry's lead sponsor class: "Industry" against every other class (universities, hospitals, government, individuals), shown here as investigator-initiated or other.
3 of the 7 Australian-site trials also have a United States site. 2 Australian-site trials and 89 United States trials are registered as recruiting.
Basis: Site countries and overall status as recorded on the registry on the fetch date. Overall status describes the whole trial, not each site.
Limits
- Registry data only. A record shows what a sponsor registered and last updated; it is not a check of what is happening at a site today.
- ANZCTR-only registrations are not yet included. Many Australian investigator-initiated trials are registered only on the Australian New Zealand Clinical Trials Registry, which has no keyless public interface, so Australian counts here are a lower bound.
- A trial is listed when a psychedelic compound (psilocybin, psilocin analogues, MDMA, LSD, DMT, 5-MeO-DMT, ayahuasca, ibogaine, mescaline or a named candidate) appears in its interventions or title. Only interventional studies are kept.
- Ketamine and esketamine are a separate group, shown only with the switch above, and only when a registry condition is psychiatric. Anaesthesia and pain trials are left out.
- Condition groups, and the split between industry and investigator-initiated or other, come from keyword rules and the registry's lead sponsor class. Some records will be grouped imperfectly.
- Audit of this snapshot: 986 records read, 530 kept; 83 not interventional, 109 without a listed compound, 264 ketamine records without a psychiatric condition.
- Population figures are 2024 resident estimates. Data fetched 20 November 2026; the snapshot is refreshed daily.